Consequently, androgen deprivation therapy (ADT), which diminishes circulating testosterone levels and blocks cellular AR signaling via surgical or chemical castration, remains the cornerstone of treatment for prostate cancer. This evidence concerns the gene AR and Familial prostate cancer.